Vitro SAB (Mexico) Performance
VITROA Stock | MXN 8.88 0.29 3.38% |
The entity has a beta of -0.22, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Vitro SAB are expected to decrease at a much lower rate. During the bear market, Vitro SAB is likely to outperform the market. At this point, Vitro SAB de has a negative expected return of -0.0095%. Please make sure to validate Vitro SAB's sortino ratio, semi variance, as well as the relationship between the Semi Variance and day median price , to decide if Vitro SAB de performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vitro SAB de has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Vitro SAB is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow | 483.9 M | |
Total Cashflows From Investing Activities | -80.5 M |
Vitro |
Vitro SAB Relative Risk vs. Return Landscape
If you would invest 900.00 in Vitro SAB de on September 27, 2024 and sell it today you would lose (12.00) from holding Vitro SAB de or give up 1.33% of portfolio value over 90 days. Vitro SAB de is generating negative expected returns and assumes 1.5873% volatility on return distribution over the 90 days horizon. Simply put, 14% of stocks are less volatile than Vitro, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
Risk |
Vitro SAB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vitro SAB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vitro SAB de, and traders can use it to determine the average amount a Vitro SAB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.006
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | VITROA |
Estimated Market Risk
1.59 actual daily | 14 86% of assets are more volatile |
Expected Return
-0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vitro SAB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vitro SAB by adding Vitro SAB to a well-diversified portfolio.
Vitro SAB Fundamentals Growth
Vitro Stock prices reflect investors' perceptions of the future prospects and financial health of Vitro SAB, and Vitro SAB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vitro Stock performance.
Return On Equity | -0.0649 | |||
Return On Asset | 0.0263 | |||
Profit Margin | (0.04) % | |||
Operating Margin | 0.05 % | |||
Current Valuation | 22.9 B | |||
Shares Outstanding | 470.03 M | |||
Price To Earning | 271.65 X | |||
Price To Book | 0.43 X | |||
Price To Sales | 4.59 X | |||
Revenue | 1.96 B | |||
EBITDA | 93.25 M | |||
Cash And Equivalents | 149.76 M | |||
Cash Per Share | 0.32 X | |||
Total Debt | 7.22 M | |||
Debt To Equity | 0.57 % | |||
Book Value Per Share | 2.63 X | |||
Cash Flow From Operations | (24.9 M) | |||
Earnings Per Share | (3.76) X | |||
Total Asset | 2.54 B | |||
About Vitro SAB Performance
By analyzing Vitro SAB's fundamental ratios, stakeholders can gain valuable insights into Vitro SAB's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vitro SAB has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vitro SAB has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
V., through its subsidiaries, manufactures, processes, distributes, and sells a range of glass products worldwide. V. was founded in 1909 and is headquartered in San Pedro Garza Garca, Mexico. VITRO SAB operates under Specialty Chemicals classification in Mexico and is traded on Mexico Stock Exchange. It employs 14556 people.Things to note about Vitro SAB de performance evaluation
Checking the ongoing alerts about Vitro SAB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vitro SAB de help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Vitro SAB de generated a negative expected return over the last 90 days | |
Vitro SAB de has high likelihood to experience some financial distress in the next 2 years | |
The company reported the revenue of 1.96 B. Net Loss for the year was (106.6 M) with profit before overhead, payroll, taxes, and interest of 437.77 M. | |
Vitro SAB de has accumulated about 149.76 M in cash with (24.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
Roughly 79.0% of the company outstanding shares are owned by insiders |
- Analyzing Vitro SAB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vitro SAB's stock is overvalued or undervalued compared to its peers.
- Examining Vitro SAB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vitro SAB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vitro SAB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vitro SAB's stock. These opinions can provide insight into Vitro SAB's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vitro Stock analysis
When running Vitro SAB's price analysis, check to measure Vitro SAB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vitro SAB is operating at the current time. Most of Vitro SAB's value examination focuses on studying past and present price action to predict the probability of Vitro SAB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vitro SAB's price. Additionally, you may evaluate how the addition of Vitro SAB to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |